Rituximab Provided Long-Term Remission in a Patient with Refractory Relapsing Thrombotic Thrombocytopenic Purpura
- 39 Downloads
We describe a 69-year-old man with refractory relapsing thrombotic thrombocytopenic purpura (TTP) successfully treated with rituximab. The patient had once been successfully treated with plasmapheresis and vincristine, but he had relapsed after a short period. Although plasmapheresis, vincristine, and splenectomy could not achieve a consistent elevation of the platelet count, rituximab administration provided sustained remission for more than 7 months. Rituximab should be considered as a therapeutic alternative for refractory TTP.
Key wordsThrombotic thrombocytopenic purpura (TTP) Rituximab von Willebrand factor-cleaving protease (VWF-CP) Anti-ADAMTS13 autoantibody
- 6.Shumak KH, Rock GA, Nair RC. Late relapse in patients successfully treated for thrombotic thrombocytopenic purpura: Canadian Apheresis Group. Ann Intern Med. 1995;44:2836–2840.Google Scholar
- 8.Kuwaan HC, Soff GA. Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 1997;34:159–166.Google Scholar
- 11.Hovinga JAK, Studt JD, Biasiutti FD, et al. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2004;89:320–324.Google Scholar